Use our pre-submission checklist
Avoid common mistakes on your manuscript.
1 Correction to: Targeted Oncology https://doi.org/10.1007/s11523-022-00875-0
The article title, which reads
“Phase I Study of Glesatinib (MGCD256) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors”
should read
“Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patnaik, A., Gadgeel, S., Papadopoulos, K.P. et al. Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors. Targ Oncol 17, 139 (2022). https://doi.org/10.1007/s11523-022-00877-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-022-00877-y